Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 11/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.48 |
| ▸ | MTOR | P42345 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30110633 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2BMTORHTR1AHTR1D | |
| SCHEMBL23202362 | 0.80 | GRIN1 (0.51) | GRIN1GRIN2BMTORMAP3K11MEN1 | |
| SCHEMBL30011997 | 0.80 | GRIN1 (0.51) | GRIN1GRIN2BMTORMAP3K11MEN1 | |
| SCHEMBL30110524 | 0.80 | ADORA3 (0.42) | GRIN1GRIN2BHTR1AHTR1DHTR1B | |
| SCHEMBL23202127 | 0.80 | ADORA3 (0.42) | GRIN1GRIN2BHTR1AHTR1DHTR1B | |
| SCHEMBL30012695 | 0.79 | GRIN1 (0.46) | GRIN1GRIN2BMTORMAP3K11PIK3CA | |
| SCHEMBL23449268 | 0.78 | BTK (0.41) | MTORHTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL23392970 | 0.71 | ALDH1A1 (0.39) | GRIN1GRIN2BMTORMAP3K11PIK3CA | |
| SCHEMBL721924 | 0.69 | GRIN1 (0.64) | GRIN1GRIN2BMAP3K11MEN1ALDH1A1 | |
| SCHEMBL23507984 | 0.66 | GRIN1 (0.70) | GRIN1GRIN2BMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055132-A1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12187759-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240116974-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11692005-B2 | TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-115427063-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| EP-4065155-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021108649-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108649-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20210155652-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155652-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | GRIN1 2296/4885GRIN2B 1775/4885MTOR 4193/4885 |
| US-20260055132-A1 | TLR7 AGONISTS | TLR7, TLR8, TLR1 | GRIN1 2441/4885GRIN2B 3279/4885MTOR 4397/4885 |
| US-20240116974-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | GRIN1 2296/4885GRIN2B 1775/4885MTOR 4193/4885 |
| US-12187759-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | GRIN1 2296/4885GRIN2B 1775/4885MTOR 4193/4885 |
| US-11692005-B2 | TLR7 agonists | TLR7, TLR1, TLR9 | GRIN1 2296/4885GRIN2B 1775/4885MTOR 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.